Two Sigma Investments LP Sells 59,670 Shares of Shattuck Labs, Inc. (NASDAQ:STTK)

Two Sigma Investments LP lowered its stake in Shattuck Labs, Inc. (NASDAQ:STTK) by 31.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 130,679 shares of the company’s stock after selling 59,670 shares during the quarter. Two Sigma Investments LP owned about 0.27% of Shattuck Labs worth $158,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Zacks Investment Management acquired a new stake in shares of Shattuck Labs during the fourth quarter worth $25,000. Virtu Financial LLC bought a new position in Shattuck Labs during the 4th quarter worth about $30,000. Schonfeld Strategic Advisors LLC bought a new position in Shattuck Labs during the 4th quarter worth about $45,000. Deutsche Bank AG raised its stake in shares of Shattuck Labs by 476.4% in the 4th quarter. Deutsche Bank AG now owns 116,868 shares of the company’s stock valued at $141,000 after purchasing an additional 96,594 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Shattuck Labs by 382.0% in the fourth quarter. JPMorgan Chase & Co. now owns 132,696 shares of the company’s stock valued at $161,000 after purchasing an additional 105,163 shares in the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Trading Down 0.9%

Shares of STTK opened at $1.07 on Friday. The company’s fifty day simple moving average is $0.97 and its 200 day simple moving average is $1.12. Shattuck Labs, Inc. has a 1-year low of $0.69 and a 1-year high of $6.99. The company has a market cap of $51.25 million, a price-to-earnings ratio of -0.70 and a beta of 1.72.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. As a group, research analysts forecast that Shattuck Labs, Inc. will post -1.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on STTK. Leerink Partners assumed coverage on Shattuck Labs in a report on Monday, March 17th. They set an “outperform” rating and a $4.00 price objective for the company. Leerink Partnrs upgraded shares of Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.